Overview

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).

Status:
Completed
Trial end date:
2020-11-12
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacokinetics, pharmacodynamics, and safety of two dose levels of tocilizumab (TCZ) administered by intravenous (IV) infusion every 4 weeks (Q4W) to participants with giant cell arteritis (GCA).
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche